1. Improvement of eye focusing function

​

Evaluations of focusing functions using TriIRIS

=> Comparison of the near point pupil diameter (NPD) variation following the VDT load, revealed a significant reduction in the left eye and the average of eyes in the BILBERON group compared to those of the placebo.

2. Improvement of eye fatigue

​

Evaluations of subjective symptoms using a questionnaire

=> After 6-weeks ingestion period, in the "Eye fatigue sensation" item, the significant improvement was indicated in BILBERON group before and after VDT load. Furthermore, the significant improvement was also showed compared with the placebo group.

3. Improvement of eye dryness

​

Evaluations of tear strip length using a Schirmer's test

=> In Bilberon group, an increased tear strip length was observed in the left eye and an average eyes after the 6-weeks ingestion period. A significant increase of tear strip length was observed in the right eye of BILBERON group compared with the placebo group.

The National Eye Institute conducted the Age-Related Eye Disease Study (AREDS) and the follow-on AREDS2 to study cataract and age-related macular degeneration (AMD). 

The Age-Related Eye Disease Study (AREDS) demonstrated beneficial effects of oral supplementation with antioxidant vitamins and minerals on the development of advanced age-related macular degeneration (AMD) in persons with at least intermediate AMD (bilateral large drusen with or without pigment changes).  Major AREDS2 findings:

• Taking AREDS2 supplements reduces the risk of progression from intermediate to advanced AMD by about 25 percent.

• Omega-3 fatty acid in eye supplements do not have an effect on cataract or AMD

• Current and former smokers should take the AREDS2 formula and avoid the AREDS formula with beta-carotene, which increases lung cancer risk